Advances in Multiple Sclerosis Research-Series I

doi:10.3390/books978-3-03943-948-5

Book License

Download Url(s)

https://mdpi.com/books/pdfview/book/3604

Contributor(s)

Matsoukas, John (editor)

Apostolopoulos, Vasso (editor)

Language

English

Show full item record

Abstract

Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials.

URI

https://directory.doabooks.org/handle/20.500.12854/68583

Keywords

multiple sclerosis; inflammation; oxidative; biomarker; sample size; autoimmune encephalitis; plasma exchange; autoimmunity; immunotherapeutics; clinical outcomes; major depression; bupropion; S-adenosylmethionine; vitamin D3; yoga; craniopharyngioma; fractionated stereotactic radiation treatments; sphenoid sinusitis; cranial nerve-VI palsy; autoimmune diseases; immune thrombocytopenic purpura; alemtuzumab; antibodies against GluR3 peptide; cognitive impairment; diagnosis; neuropsychological assessment; short intracortical inhibition; intracortical facilitation; fampridine; walking disability; TSPAN32; tetraspanins; cellular immunity; memory T cells; tDCS; neuroimaging; positron emission tomography; cerebral blood flow; probiotics; Streptococcus thermophilus; ST285; MBP83–99 peptide; mannan; immune modulation; agonist peptide; gut microbiome; gut–brain axis; metagenomics; disease-modifying treatments; MS; vaccine; immunomodulation; carriers; B cell receptor; delivery methods; immunotherapy; monoclonal antibodies; T cell receptor; tolerance; diagnostic markers; immunoglobulins; kappa; free light chains; antigen-specific immunotherapies; tolerogenic vaccines; tolerance induction; central nervous system; myelin peptides; myelin basic protei; proteolipid protein; myelin oligodendrocyte glycoprotein; nanotechnology; drug delivery nanosystems; lipids; polymers; vaccines; nanoparticles; antigen-specific immunotherapy; experimental autoimmune encephalomyelitis; neurodegeneration; chloroquine; EAE; dendritic cells; microglia; astrocytes; oligodendrocytes; conformational analysis; peptides; altered peptide ligands; NMR spectroscopy; NOE-constraints; molecular dynamic; trimolecular complex; Multiple Sclerosis; early-onset; adult-onset; Human Leucocyte Antigens; immunogenetics; clinical phenotype; clinical outcome; therapeutics; antibody detection; ELISA; multivalency; N-glucosylated peptide epitopes; peptide; conjugation; MOG35-55; Graphite/SiO2 electrode; voltammetry; HPLC; MS drugs